AH

Akseli Hemminki

Chief Executive Officer

TILT Biotherapeutics Ltd

Espoo, Uusimaa


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
TILT Biotherapeutics Ltd
Industry
research
Employees
28.0
Seniority
C suite
Annual Revenue
4000000.0
Total Funding
44202988.0
Latest Funding
Other

Technologies

Outlook Microsoft Office 365 YouTube Apache Mobile Friendly Typekit AI

Keywords

oncolytic viruses solid tumors cancer immunotherapy oncoimmunology tcell therapy immune checkpoint inhibitors biotechnology research oncolytic immunotherapy tilt-123 cancer treatment t-cell stimulation cytokine therapy adenoviral vector tumor microenvironment checkpoint inhibitors car t therapy immuno-oncology phase 1 clinical trials clinical pipeline biotechnology tumor-infiltrating lymphocytes intravascular administration immune response enhancement cancer vaccines antitumor efficacy biologics cancer immunotherapy clinical research cancer therapeutics il-2 tnf alpha chimeric adenovirus safety profile combination therapies systemic delivery preclinical models cancer cell selectivity biomedical innovation scientific publications research & development university collaboration european innovation council business finland patent portfolio market potential targeted cancer therapy molecular profiling immune system modulation therapeutic strategies intratumoral injection investor relations business development clinical advancements future of immunotherapy b2b

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans